NCCN Guidelines® Insights
Featured Updates to the NCCN Guidelines

Crystal S. Denlinger, MD1,*; Jennifer A. Ligibel, MD2,*; Madhuri Are, MD3,*; K. Scott Baker, MD, MS5; Gregory Broderick, MD6; Wendy Demark-Wahnefried, PhD, RD5; Debra L. Friedman, MD, MS5; Mindy Goldman, MD6; Lee W. Jones, PhD5; Allison King, MD10; Grace H. Ku, MD11,*; Elizabeth Kvale, MD4,*; Terry S. Langbaum, MAS12; Mary S. McCabe, RN, BS, MA13; Michelle Melisko, MD4; Jose G. Montoya, MD15; Kathi Mooney, RN, PhD16; Mary Ann Morgan, PhD, FNP-BC17,*; Javid J. Mosleh, MD13; Tracey O’Connor, MD19; Linda Overholser, MD, MPH17; Electra D. Paskett, PhD18,*; Jeffrey Peppercorn, MD, MPH6,*; M. Alma Rodriguez, MD7; Kathryn J. Ruddy, MD, MPH8,*; Tara Sanft, MD14,*; Paula Silverman, MD, MS19; Karen L. Syrjala, PhD4,*; Susan G. Urba, MD20; Mark T. Wakabayashi, MD, MPH21; Phyllis Zee, MD26; Nicole R. McMillian, MS27,*; and Deborah A. Freedman-Cass, PhD22.*

Abstract
The NCCN Guidelines for Survivorship provide screening, evaluation, and treatment recommendations for common consequences of cancer and cancer treatment. They are intended to aid health care professionals who work with survivors of adult-onset cancer in the posttreatment period, including those in general oncology, specialty cancer survivor clinics, and primary care practices. Guidance is also provided to help promote physical activity, weight management, and proper immunizations in survivors. This article summarizes the NCCN Survivorship panel’s discussions for the 2016 update of the guidelines regarding the management of anxiety, depression, posttraumatic stress disorder–related symptoms, and emotional distress in survivors.

From 1Fox Chase Cancer Center; 2Dana-Farber/Brigham and Women’s Cancer Center; 3Fred & Pamela Buffett Cancer Center; 4Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance; 5Mayo Clinic Cancer Center; 6University of Alabama at Birmingham Comprehensive Cancer Center; 7Vanderbilt-Ingram Cancer Center; 8UCSF Helen Diller Family Comprehensive Cancer Center; 9Memorial Sloan Kettering Cancer Center; 10Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine; 11UC San Diego Moores Cancer Center; 12The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; 13Stanford Cancer Institute; 14Huntsman Cancer Institute at the University of Utah; 15Moffitt Cancer Center; 16Roswell Park Cancer Institute; 17University of Colorado Cancer Center; 18The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute; 19Massachusetts General Hospital; 20The University of Texas MD Anderson Cancer Center; 21Yale Cancer Center/Smilow Cancer Hospital; 22Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute; 23Duke Cancer Institute; 24University of Michigan Comprehensive Cancer Center; 25City of Hope Comprehensive Cancer Center; 26Robert H. Lurie Comprehensive Cancer Center of Northwestern University; and 27National Comprehensive Cancer Network.

*Provided content development and/or authorship assistance.

Please Note
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) are a statement of consensus of the authors regarding their views of currently accepted approaches to treatment. The NCCN Guidelines® Insights highlight important changes to the NCCN Guidelines® recommendations from previous versions. Colored markings in the algorithm show changes and the discussion aims to further the understanding of these changes by summarizing salient portions of the NCCN Guidelines Panel discussion, including the literature reviewed.

These NCCN Guidelines Insights do not represent the full NCCN Guidelines; further, the National Comprehensive Cancer Network® (NCCN®) makes no representation or warranties of any kind regarding the content, use, or application of the NCCN Guidelines and NCCN Guidelines Insights and disclaims any responsibility for their applications or use in any way.

The full and most current version of these NCCN Guidelines are available at NCCN.org.

© National Comprehensive Cancer Network, Inc. 2016, All rights reserved. The NCCN Guidelines and the illustrations herein may not be reproduced in any form without the express written permission of NCCN.
NCCN: Continuing Education

Accreditation Statement

This activity has been designed to meet the educational needs of physicians, nurses, and pharmacists involved in the management of patients with cancer. There is no fee for this article. The National Comprehensive Cancer Network (NCCN) is accredited by the ACCME to provide continuing medical education for physicians. NCCN designates this journal-based CE activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

NCCN is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

NCCN designates this educational activity for a maximum of 1.0 contact hour. Accreditation as a provider refers to recognition of educational activities only; accredited status does not imply endorsement by NCCN or ANCC of any commercial products discussed/displayed in conjunction with the educational activity. Kristina M. Gregory, RN, MSN, OCN, is our nurse planner for this educational activity.

Disclosure of Relevant Financial Relationships

Editor:

Kerrin M. Green, MA, Assistant Managing Editor, JNCCN—Journal of the National Comprehensive Cancer Network, has disclosed that she has no relevant financial relationships.

CE Authors:

Deborah J. Moonan, RN, BSN, Director, Continuing Education, NCCN, has disclosed that she has no relevant financial relationships.

Ann Gianola, MA, Senior Manager, Continuing Education Accreditation & Program Operations, NCCN, has disclosed that she has no relevant financial relationships.

Kristina M. Gregory, RN, MSN, OCN, Vice President, Clinical Information Operations, NCCN, has disclosed that she has no relevant financial relationships.

Rashmi Kumar, PhD, Senior Manager, Clinical Content, NCCN, has disclosed that she has no relevant financial relationships.

Individuals Who Provided Content Development and/or Authorship Assistance:

Crystal S. Denlinger, MD, Panel Chair, has disclosed that she is a scientific advisor for Eli Lilly and Company and Merrimack Pharmaceuticals.

Jennifer A. Ligibel, MD, Panel Vice Chair, has disclosed that she has received a product donation from Fitbit for a research study.

Madhuri Are, MD, Panel Member, has disclosed that she has no relevant financial relationships.

Grace H. Ku, MD, Panel Member, has disclosed that she has no relevant financial relationships.

Elizabeth Kvale, MD, Panel Member, has disclosed that she is a consult for Aspire Healthcare.

Mary S. McCabe, RN, BS, MA, Panel Member, has disclosed that she has no relevant financial relationships.

Mary Ann Morgan, PhD, FNP-BC, Panel Member, has disclosed that she is on the speakers’ bureau for Genentech.

Electra D. Paskett, PhD, Panel Member, has disclosed that she has equity interest/stock options from Pfizer Inc, and receives grant/research support from Merck & Co., Inc.

Jeffrey Peppercorn, MD, MPH, Panel Member, has disclosed that he has equity interest/stock options and receives salary from GlaxoSmithKline, and receives grant/research support from Pfizer Inc.

Kathryn J. Ruddy, MD, MPH, Panel Member, has disclosed that she has no relevant financial relationships.

Tara Sanft, MD, Panel Member, has disclosed that she has no relevant financial relationships.

Karen L. Syrjala, PhD, Panel Member, has disclosed that she has no relevant financial relationships.

Nicole R. McMillian, MS, Guidelines Coordinator, NCCN, has disclosed that she has no relevant financial relationships.

Deborah A. Freedman-Cass, PhD, Oncology Scientist/Senior Medical Writer, NCCN, has disclosed that she has no relevant financial relationships.

This activity is supported by educational grants from AstraZeneca, Bayer Healthcare Pharmaceuticals Inc., Bristol-Myers Squibb, Clovis Oncology, Foundation Medicine, Genentech, Novartis Oncology, Otsuka America Pharmaceutical, Inc., Seattle Genetics, Inc., and Takeda Oncology; support provided by Actelion Pharmaceuticals US, Inc.; and by an independent educational grant from Astellas and Medivation, Inc.

Learning Objectives:

Upon completion of this activity, participants will be able to:

- Integrate into professional practice the updates to NCCN Guidelines for Survivorship
- Describe the rationale behind the decision-making process for developing the NCCN Guidelines for Survivorship

Release date: June 10, 2016; Expiration date: June 10, 2017


GENERAL PRINCIPLES OF ANXIETY, DEPRESSION, AND DISTRESS

- The NCCN Guidelines for Distress Management define distress as “a multifactorial unpleasant emotional experience of a psychological (ie, cognitive, behavioral, emotional), social, and/or spiritual nature that may interfere with the ability to cope effectively with cancer, its physical symptoms, and its treatment.”

- Survivors of cancer treatment are at high risk for fear of recurrence, distress, anxiety, and depression due to the multiple challenges they face.
  - Fear of recurrence can lead to increased symptoms when surveillance testing or follow-up appointments are scheduled and increased anxiety when physical symptoms occur that may or may not be similar to those experienced during the cancer diagnosis.
  - Medical, psychosocial, environmental, and psychiatric health factors may affect the mood of cancer survivors and need to be considered when screening for distress, anxiety, and depression in survivors and deciding on treatment. (See SANXDE-6)
  - Recurrent worry, fear, thoughts, or images related to cancer events should be distinguished from obsessive compulsive disorders. Repetitive, persisting thoughts, images, or behaviors or mental acts that a person is compelled to perform, aimed at reducing intense anxiety or preventing a dreaded event require psychiatric referral for evaluation and treatment.
  - Monitor distress, especially at times of transitions in care, cancer surveillance, significant loss, other major life events, and with social isolation.
  ◊ Patients may not appear to be distressed and should be encouraged to inform their health care provider when they are feeling increased distress, anxiety, or depression. See DIS-B from the NCCN Guidelines for Distress Management.

- This algorithm is intended for oncologists and other health care providers to screen for distress, anxiety, and depression in cancer survivors, to provide steps for addressing these concerns with survivors, and to facilitate decisions about referral to specialists.
  - The algorithm is not intended as a psychiatric diagnosis and treatment tool.
  - The algorithm focuses on more common mood disorders after cancer; it does not screen or address treatment for psychiatric conditions such as bipolar disorders, schizophrenia, personality disorders, or obsessive compulsive disorders.

- Decisions about treatment and referral will depend on the acuteness of onset of symptoms, their intensity, and safety of the survivor and others. (See SANXDE-6 and SANXDE-A)

Overview

Nearly 14.5 million cancer survivors were alive in the United States in 2014, and these numbers are predicted to reach almost 19 million by 2024.1,2 Unfortunately, many of these survivors experience physical (eg, fatigue, pain, lymphedema, premature menopause, cognitive deficits, sexual dysfunction), psychological (eg, anxiety, depression, fear of recurrence), and psychosocial (eg, issues surrounding employment, finances, insurance) late and long-term effects of cancer and its treatment.1-22 These effects can be severe, debilitating, and sometimes permanent or life-threatening. Survivors may be discharged from the care of their oncologist or see the oncology team less frequently, resulting in feelings of isolation and worry or fear. Furthermore, their primary care physicians (PCPs), who may now be responsible for their care, often do not know how best to care for the specific concerns and needs of cancer survivors.23

NCCN Categories of Evidence and Consensus

Category 1: Based upon high-level evidence, there is uniform NCCN consensus that the intervention is appropriate.

Category 2A: Based upon lower-level evidence, there is uniform NCCN consensus that the intervention is appropriate.

Category 2B: Based upon lower-level evidence, there is NCCN consensus that the intervention is appropriate.

Category 3: Based upon any level of evidence, there is major NCCN disagreement that the intervention is appropriate.

All recommendations are category 2A unless otherwise noted.

Clinical trials: NCCN believes that the best management for any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
SCREENING: ANXIETY AND DEPRESSION

Screening questions\(^a\) to be asked at regular intervals, especially when there is a change in clinical status or treatment, or patient presents with multiple somatic complaints:\(^c\):

- In the past two weeks have you:
  - Nervous/anxious
    - had worries or fears related to your cancer?
    - felt nervous, or worried about other things?
    - had trouble controlling your worry?
  - Sad/depressed
    - had less interest or enjoyment in activities than usual?
    - felt sad or depressed?
  - Additional screening for impact of mood on quality of life if “Yes” to any of the above:
    - had difficulty performing daily activities because of these (above mentioned) feelings or problems?
    - had trouble sleeping (eg, staying asleep, falling asleep, too much sleep)\(^a\)
    - had difficulty concentrating?\(^a\)

\(^a\)A positive response to any of the questions should result in further assessment. However, if a patient has an isolated problem with sleep or concentration in the absence of other symptoms, refer to the Sleep Disorders Guidelines (SSD-1) or Cognitive Function Guidelines (SCF-1).

\(^c\)If the NCCN Distress Thermometer is used as a primary screening tool, these questions would follow for those survivors with an elevated level of distress.

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Survivorship aid health care professionals who work with survivors of adult-onset cancers in the posttreatment period by providing screening, evaluation, and treatment recommendations for common consequences of cancer and cancer treatment. The guidelines are designed to provide a framework for the management of long-term and/or late effects of cancer and its treatment and for the coordination of care between the survivor’s health care providers to ensure that needs are appropriately addressed. They should be used as a supplement to the follow-up recommendations within the disease-specific guidelines (see NCCN Guidelines for Treatment of Cancer by Site, available at www.NCCN.org).

The 1.2016 version of the NCCN Guidelines for Survivorship focuses on several common issues of survivors: anxiety/depression/distress; anthracycline-induced cardiac toxicity; cognitive decline; fatigue; pain; female and male sexual dysfunction; sleep disorders; and the preventive health issues of immunizations and prevention of infections and healthy lifestyle behaviors. Additional topics will be addressed in subsequent updates.

2016 Updates to the NCCN Guidelines for Survivorship

During the update of the NCCN Guidelines for Survivorship this year, an emerging theme highlighted the fact that clinicians may not have the expertise needed to help survivors with the wide range of possible issues they may face. The panel therefore added the option for early referral to the appropriate specialist in many cases (eg, sexual dysfunction, sleep disorders). Thus, the algorithm for many of the survivorship topics now first includes information designed to increase clinician awareness of the issues, then includes appropriate screening questions or tools followed by the option for early referral to the appropriate specialist. In addi-

SCREENING: POST-TRAUMATIC STRESS DISORDER (PTSD)-RELATED SYMPTOMS

DIAGNOSIS OF PTSD REQUIRES SYMPTOMS FROM EACH OF THE FOLLOWING 4 CATEGORIES

Exposure to traumatic events (eg, cancer diagnosis, treatment) and the following symptoms that cause clinically significant distress or impairment in social interactions, capacity to work, or other functioning for more than 1 month:

- Re-experiencing: repeated, disturbing memories, dreams, or flashbacks (minimum 1 symptom)
- Persistent avoidance: avoidance of distressing memories, thoughts, feelings, or external reminders of the cancer experience (minimum 1 symptom)
- Negative alterations in mood or cognition: exaggerated negative beliefs about oneself or the world, feeling detached or estranged from others, lack of positive emotions, feelings of fear, horror, anger, guilt, or shame (minimum 2 symptoms)
- Arousal: aggressive, risky or self-destructive behavior, sleep disturbance, hypervigilance (being super-alert or watchful or on guard), difficulty concentrating (minimum 2 symptoms)

DIAGNOSIS

- Post-traumatic stress disorder symptoms impacting quality of life
- Consider PTSD
- Consider adjustment disorder/distress (see SANXDE-6)

See Evaluation (SANXDE-7) or Refer to mental health services for evaluation and treatment

SANXDE-4

Anxiety, Depression, and Distress in Survivors

Cancer survivors are at especially high risk for anxiety, depression, and other forms of psychosocial distress because of the multiple stressors, vulnerabilities, and challenges they face. According to the NCCN Guidelines for Distress Management (available at www.NCCN.org), risk factors for psychosocial distress include cognitive impairment, severe comorbid illnesses, uncontrolled symptoms, communication barriers, or a history of psychiatric disorder, depression, or substance abuse. Social issues, such as living alone, having young children, being of younger age or female, and prior physical or sexual abuse, are also risk factors for psychosocial distress.

Fear of recurrence, with persisting worry and distress sometimes reaching levels of clinical anxiety, is common in cancer survivors. This fear can increase at times of routine cancer surveillance testing or with physical symptoms that may or may not be related to the cancer diagnosis. Anxiety and/or depression can also occur in survivors secondary to physical compromise, social isolation, or work and financial problems that result from cancer treatment. These challenges are underscored by the inevitable decreased medical and interpersonal support after completion of treatment and transition to the surveillance stage.

Anxiety and depression affect up to 29% of survivors, with 1% to 19% of survivors reportedly
meeting the criteria for PTSD.\textsuperscript{11,15,29–31} In addition, many survivors have less severe distress that might not lead to a clinical diagnosis of anxiety, depression, or PTSD but that can still have a negative impact on quality of life. Survivors with untreated, uncontrolled emotional distress are less likely to adhere to recommended surveillance and are less likely to engage in health-promoting activities, such as exercise and smoking cessation.\textsuperscript{32} Sometimes these individuals develop thoughts of ending their lives; the incidence of completed suicide among patients with cancer and survivors in the United States is approximately twice that of the general population.\textsuperscript{33–38}

**Possible Early Referral for Survivors With Anxiety, Depression, PTSD-Related Symptoms, and Distress:** Reviewers from several NCCN Member Institutions indicated that the original anxiety and depression section of the guidelines was too complex, detailing evaluation and management that were beyond the scope of the typical oncologist or PCP. The extensive evaluation was viewed as a diagnostic evaluation better performed by a trained mental health provider.

Oncologists on the panel agreed that they do not feel comfortable diagnosing major psychiatric disorders, nor should oncologists or PCPs be doing so. However, the panel discussed the pervasiveness of psychosocial problems in survivors and the fact that many distressed survivors may not appear distressed. The panelists strongly believe that oncologists and PCPs need to know how to screen, when to screen, and to whom to refer when screening indicates a need for services. The panel therefore added information on the prevalence of and risk factors for distress in survivors (see SANXDE-1; page 717) and modified their recommendations to include the following general structure: screening, flagging those in need of referral, ensuring the safety of the survivor, and the option for early referral to mental health services (ie, psychiatrist, psychologist, advanced practice cli-

RISK FACTORS FOR PTSD

- Physical
  - Recurrence of cancer
  - Intensive treatment (e.g., bone marrow/stem cell transplant)
  - Advanced disease
  - Younger age
- Psychosocial
  - Exposure to previous trauma (e.g., combat, sexual assault, major loss)
  - History of mental health issues prior to cancer
  - Poor coping skills (e.g., using avoidance)
  - Lower income and/or less education
  - Less social support

The panel then discussed the fact that survivors with few or mild symptoms may be managed with oncology or primary care support and access to online, telephone-based, or community support resources, and may not require a referral to mental health services, and that in some places (e.g., rural areas) there may not be sufficient mental health resources available to refer all survivors in need. It is important for oncology and PCPs to have awareness of the prevalence of anxiety, depression, and distress in survivors and guidance regarding initial steps in management. In addition, the panelists felt that guidance for the psychiatrists, psychologists, advanced practice clinicians, social workers, and/or licensed therapists who work with survivors was needed. The panel therefore retained the evaluation and management recommendations listed in the guidelines.

**Screening:** During the panel’s discussion regarding the appropriate initial screening for anxiety and depression in survivors, a panel member brought up the role of the NCCN Distress Thermometer (DT) in survivors. Several panel members noted that their institutions are using the DT to screen for distress in survivors at this time. The DT is embedded into many commercially available electronic health record (EHR) systems and is therefore used by many hospitals, clinics, and private practices.

The panel discussed the literature addressing the validity of the DT in cancer survivors. Studies generally do not support its use in a clinical survivorship setting because it lacks sufficient sensitivity and specificity in this population. For example, a study of 120 survivors of adult-onset cancer found that the DT had a sensitivity of 47.6% and 51.7%, using cutoff values of 5 and 4, respectively. The panel therefore recommended supplemental screening when the DT is used as an initial screening tool. They added a footnote indicating that survivors with an elevated level of distress by the DT should still be asked the initial screening questions provided by the panel (see SANXDE-2, page 718). These more specific questions allow the clinician to determine what particular issues are affecting the survivor and may identify more distressed or depressed survivors than the DT.

Distress/Adjustment Disorder: Reviewers from NCCN Member Institutions commented that the guidelines seemed mainly to address severe or extreme cases of anxiety and depression, but gave little guidance for cases of mild to moderate symptom burden, which are most common. Reviewers also suggested combining “mild adjustment disorder with depressed mood or with mixed depressed mood and anxiety” with “adjustment disorder with anxious mood,” noting that no clinical reasons justified their separation within the guidelines.

The panel agreed with these points. Panelists noted that many survivors may not have clinical diagnoses but still have symptoms that require further evaluation and intervention. Such survivors have what the NCCN Guidelines for Distress Management (available at www.NCCN.org) define as distress: “a multifactorial unpleasant emotional experience of a psychological (ie, cognitive, behavioral, emotional), social, and/or spiritual nature that may interfere with the ability to cope effectively with cancer, its physical symptoms, and its treatment.” Distress, often related to fear of recurrence, is common in survivors, and can negatively impact quality of life.

The panel decided to restructure the guidelines to include a page for all survivors with symptoms who do not meet the diagnostic criteria for anxiety or depression and who do not have PTSD symptoms impacting quality of life (see SANXDE-6; page 720). This page addresses what the panel termed “adjustment disorder/distress.” To emphasize the importance of treating distress, the panel also changed the title of this section of the guideline to include the word “distress.”

PTSD-Related Symptoms: A panel member asked the panel to discuss PTSD, noting that, as with distress, many survivors may not meet the full diagnostic criteria for PTSD but still have PTSD-related symptoms that need to be addressed. However, the way the guideline was originally written only allowed for patients to be treated if they had full PTSD. The panel discussed various studies showing that 17% to 38% of survivors have PTSD symptoms, whereas 1% to 19% meet the full criteria. In one longitudinal study, 12% of survivors reported that their PTSD symptoms resolved over 5 years, whereas 37% reported that their symptoms persisted or worsened during that time. Panel members also pointed out that PTSD symptoms in survivors can fluctuate over time, because of other events or other trauma occurring in the survivor’s life.

The panel decided to expand the section on PTSD, changing it to “PTSD-related symptoms” to emphasize the fact that survivors may not meet the full diagnostic criteria for PTSD but still have symptoms deserving of treatment (see SANXDE-4, page 719). The panel included an extensive list of PTSD criteria, so that clinicians can be aware when a survivor might have PTSD. The panel also decided to add a list of risk factors for PTSD, so that clinicians are alert to the disease-related and other physical and psychosocial factors that can play a role in the disorder (see SANXDE-B, page 721). In addition, the guidelines now allow for further evaluation, referral, and treatment for survivors with PTSD-related symptoms impacting quality of life, even if the full PTSD diagnostic criteria are not met.

Conclusions

The diagnosis and treatment of cancer can have a vast and persistent impact on the survivor’s health, physical, and mental states; health behaviors; professional and personal identity; sexuality; and financial standing. Clinicians providing survivorship care can improve the lives of the survivors by understanding this impact; conducting screening for physical, psychological, and psychosocial effects; and providing appropriate referrals, treatment, and/or follow-up.

As the number of survivors continues to grow, clinician awareness about these critical issues becomes increasingly important. In particular, clinicians who work with cancer survivors need to be aware that distress is prevalent in the survivor population and may not be evident in an individual survivor without appropriate screening. Distressed survivors may not meet criteria for a full clinical psychiatric diagnosis, but can still benefit from interventions to improve quality of life. Clinicians can refer distressed survivors to an appropriate mental health professional or but can still benefit from interventions to improve quality of life. Clinicians can refer distressed survivors to an appropriate mental health professional or can perform evaluation and treatment as their expertise and resources allow.

References


Instructions for Completion
To participate in this journal CE activity: 1) review the learning objectives and author disclosures; 2) study the education content; 3) take the posttest with a 66% minimum passing score and complete the evaluation at http://education.nccn.org/node/78599; and 4) view/print certificate. After reading the article, you should be able to answer the following multiple-choice questions. Credit cannot be obtained for tests completed on paper. You must be a registered user on NCCN.org. If you are not registered on NCCN.org, click on “New Member? Sign up here” link on the left hand side of the Web site to register. Only one answer is correct for each question. Once you successfully answer all posttest questions you will be able to view and/or print your certificate. Software requirements: Internet

Posttest Questions
1. True or False: Studies generally do not support the use of the NCCN DT as a stand-alone screening tool in a clinical survivorship setting because it lacks sufficient sensitivity and specificity in this population.
2. Which of the following PTSD-related symptoms may impact quality of life in cancer survivors:
   a. Repeated, disturbing memories, dreams, or flashbacks
   b. Avoiding medical appointments
   c. Feeling detached or estranged from others
   d. Sleep disturbance
   e. Hypervigilance
   f. All of The above
3. Which of the following behaviors have NOT been shown to be associated with uncontrolled emotional distress in survivors?
   a. Lack of adherence to recommended surveillance
   b. Lack of exercise
   c. Avoidance of immunizations
   d. Smoking
   e. Suicide